The problem of the cardiomyopathies]

The author criticizes the tendency to broaden continuously the notion of "cardiomyopathy" and the attempts to cover by this term almost all etiological and pathogenetic variants of myocardial lesions. Classification of these variants by two groups is proposed: 1) idiopathic cardiomyopathies, etiology of which are either not known, or not established yet; 2) symptomatic cardiomyopathies the causes of which are known. The first group comprises congestive and hypertrophic cardiomyopathies. Their essential clinico-anatomical features and considerations concerning pathogenesis are set forth. Every variant of the second group of cardiomyopathies (symptomatic) is analysed separately according to the character of the pathogenic agent. The need for comprehensive study of myocardial pathology in the so-called cardiomyopathies is emphasized.     

我国HIV-1 B''亚型毒株gag基因变异特征研究

目的研究我国人免疫缺陷病毒1型（HIV-1）B’亚型主要流行株在宿主免疫压力下的基因变异及抗原表位的变化特征，探讨选择压力、基因离散率和抗原表位变化之间的关系。方法从确诊的HIV-1感染者的全血样本中提取基因组DNA，经套式聚合酶链反应（PCR）扩增后，将扩增产物进行纯化和测序。然后将所得序列进行系统进化树和氨基酸变异分析，使用GCG软件包的Distance程序对P17和P24两个区段计算基因距离，用Diverge程序计算同义替换（1（s）和非同义替换（1（a）及二者之间的比值，并对我国人群中较常见的HLA型别限制的CTL表位的突变情况进行分析。结果HIV-1B’亚型毒株的P17区段的Ks／Ka值〈1，而P24区段的Ks／Ka值〉1；P24部分的基因离散率低于P17部分；P17区段抗原表位的保守率为34．94％，而P24区段抗原表位的保守率为67．38％；从基因离散率、所受的选择压力及抗原表位的突变率3个方面来看，HIV-1的P17区段均明显大于P24区段。结论HIV-1B’亚型毒株的P17区段的抗原表位变化较大，而P24区段的抗原表位相对较为保守。提示P24区段的CTL表位更适合于表位疫苗的研制。     

Methods for obtaining and analyzing unattended polysomnography data for a multicenter study. Sleep Heart Health Research Group

This paper reviews the data collection, processing, and analysis approaches developed to obtain comprehensive unattended polysomnographic data for the Sleep Heart Health Study, a multicenter study of the cardiovascular consequences of sleep-disordered breathing. Protocols were developed and implemented to standardize in-home data collection procedures and to perform centralized sleep scoring. Of 7027 studies performed on 6697 participants, 5534 studies were determined to be technically acceptable (failure rate 5.3%). Quality grades varied over time, reflecting the influences of variable technician experience, and equipment aging and modifications. Eighty-seven percent of studies were judged to be of "good" quality or better, and 75% were judged to be of sufficient quality to provide reliable sleep staging and arousal data. Poor submental EMG (electromyogram) accounted for the largest proportion of poor signal grades (9% of studies had <2 hours artifact free EMG signal). These data suggest that with rigorous training and clear protocols for data collection and processing, good-quality multichannel polysomnography data can be obtained for a majority of unattended studies performed in a research setting. Data most susceptible to poor signal quality are sleep staging and arousal data that require clear EEG (electroencephalograph) and EMG signals.     

森林脑炎病毒prM-E蛋白在昆虫细胞中的表达及免疫活性测定

目的为了表达森林脑炎病毒prME蛋白,为森林脑炎快速诊断试剂的研制奠定基础。方法经过RTPCR扩增、重组转移载体构建、细菌内转座和昆虫细胞转染,以杆状病毒昆虫细胞表达系统成功地表达了森林脑炎病毒MDJ01株prME蛋白。结果从感染细胞上清中电镜观察到重组蛋白形成的球型颗粒,说明重组病毒感染细胞后产生病毒样表达颗粒(viruslikeparticlesVLPs),并且分泌至细胞外。免疫印迹试验和间接免疫荧光试验表明,表达的重组蛋白能够与抗森林脑炎病毒抗体特异结合,具有良好的抗原性。ELISA和间接免疫荧光染色证实,重组prME蛋白可以作为抗原用于检测患者血清特异性抗体。结论在昆虫细胞中表达的prME具有良好的抗原性,本研究为森林脑炎快速特异诊断试剂研制奠定了基础。     

人乳头瘤病毒18型L1-E6、L1-E7嵌合基因表达载体的构建及表达

目的 构建HPV 18 L1－E6，L1－E7嵌合基因的表达载体，并在CHO细胞中表达。方法 克隆HPV18 L1－E6和L1－E7基因，插入中介载体pGEMT-Easy中并测序鉴定。采用PCR定点突变法，突变L1－E6，L1－E7基因序列中与转化作用相关的位点，分别与L1基因连接后插入真核表达载体pVAX1，构建真核表达质粒pVAX-1L1 E6Mxx,L1E7Mxx。用磷酸钙沉淀法，转染CHO细胞，以抗HPV－18L1，抗E6和抗E7特异性单克隆抗体（mAb)做ELISA和免疫细胞化学法检测。结果 ELISA检测显示，转染各种pVAX1-LIE6Mxx-L1E7Mxx融合蛋白表达质粒的细胞提取物的P－N值均＞2．1；免疫细胞化学检测，在胞浆，胞核可见棕黄色颗粒。结论 我建的pVAX1-L1E6Mxx-E7Mxx融合蛋白质表达质粒，可在转当细胞内表达相应的L1－E6Mxx和L1－E7Mxx蛋白，为今后进行DNA疫苗的研究奠定了基础。     

重组人乳头瘤病毒6型病毒样颗粒的免疫原性分析

目的　研究重组人乳头瘤病毒 6型 (humanpapillomavirustype 6 ,HPV 6 )病毒样颗粒(virus likeparticle ,VLP)的免疫原性。方法　重组杆状病毒在昆虫细胞中表达制备的HPV 6L1VLP(L1 VLP)和HPV 6L1+L2VLP(L1+2 VLP)经鉴定后 ,用于免疫BALB/c小鼠 ,对诱导的体液免疫和细胞免疫反应进行了检测。结果　电镜观察显示L1 VLP和L1+2 VLP二者形态上无明显差异 ,为圆形颗粒 ,直径约 5 0nm ,SDS PAGE和Westernblot分析表明 ,L1+2 VLP中L1和L2蛋白摩尔比例为 4∶1。用ELISA法测定免疫小鼠血清抗体滴度 ,加佐剂L1 VLP免疫组和加佐剂L1+2 VLP免疫组血清针对HPV 6L1VLP的滴度在 1∶10 0 0 0以上 ,高于未加佐剂组免疫血清滴度 (1∶2 0 0 0 ) ,L1+2 VLP免疫诱导出了特异于L2抗原的抗体。血清抗体主要识别HPV 6构象依赖性抗原表位 ,与HPV 11抗原显示出一定的交叉反应 ,而与HPV 16无明显交叉反应。免疫小鼠脾淋巴细胞体外经HPV 6L1VLP再激活后出现了特异性增殖反应 ,3H TdR掺入值与未免疫组之间差异有显著性 (P <0 .0 1) ,L1 VLP和L1+2 VLP两组间差异无显著性 (P >0 .0 5 ) ,L1 VLP和L1+2 VLP免疫组刺激指数 (SI)分别为 6 .4和 6 .2 ,阴性对照组SI为 1.1。HPV 6L1VLP再刺激特异地诱导免疫组脾淋巴细胞IL 2和IL 10分     

Evidence for a potential common T-cell epitope between human thyroid peroxidase and human thyroglobulin with implications for the pathogenesis of autoimmune thyroid disease

In order to explore the possibility that, in autoimmune thyroid disease, anti-thyroglobulin (Tg) and anti-thyroid peroxidase (TPO) antibodies arise concurrently because they share a common T-cell epitope, we performed a detailed comparative analysis of the cDNA nucleotide sequences corresponding to these two genes. We discovered an 8 amino acid region (Leu-Ser-Glu-Asp-Leu-Leu-Ser- Ile in human TPO) in which there were 6 identical and 2 conserved amino acid residues when compared with human Tg. This remarkably similar region is near the amino-terminus of human TPO (residues 119-126) and the carboxyl-terminus of human Tg (residues 2763-2770). A second feature of interest was that this region of homology conforms to the Rothbard algorithm for a T-cell epitope. Third, probing of the Swiss-protein data bank (10,008 proteins containing 2,952,765 amino acids) with the human TPO region revealed greater homology for human Tg than for any other eukaryotic protein. Two bacterial proteins (E. coli aminopeptidase N and stringent starvation protein) had higher homology scores from human TPO than did human Tg. Our findings provide circumstantial evidence that human TPO and human Tg, and possibly certain bacterial proteins, do indeed share common T-cell epitopes that may play a role in the pathogenesis of autoimmune thyroid disease.     

恶性疟原虫FCC1/HN株环子孢子蛋白的原核表达、纯化及其对肝细胞靶向作用的观察

目的从恶性疟原虫FCC1／HN株基因组中扩增得到环子孢子蛋白(circumsporozoite protein,CSP)的全长编码基因,克隆至原核表达载体pET-32c中进行表达纯化,观察重组环子孢子蛋白对肝细胞的结合能力,探讨其作为原发性肝癌基因治疗的靶向分子的可行性。方法根据恶性疟原虫3D7株环子孢子蛋白的编码序列设计一对引物,利用聚合酶链反应(PCR)技术从恶性疟原虫FCC1／HN株基因组中扩增出CSP的全长编码基因,将其克隆到载体pGEM-T中,通过基因测序加以证实;进一步亚克隆至原核表达载体pET-32c中,在大肠杆菌BL21中用IPTG诱导表达,表达产物用Ni2+螯合柱亲和纯化,采用免疫印迹技术(WB)对纯化的融合蛋白进行免疫反应性检测;采用免疫组化(IHC)技术观察重组环子孢子蛋白对不同组织细胞的结合能力。结果从恶性疟原虫FCC1／HN株基因组中成功扩增到1263 bp的全长CSP基因,该基因在原核系统中经诱导表达出一相对分子质量(Mr)约62×103大小的融合蛋白,表达产物以包涵体的形式存在;通过Ni2+亲和柱纯化获得重组CSP融合蛋白;WB表明,重组CSP融合蛋白能被疟原虫阳性血清特异性识别;免疫组化结果显示重组CSP融合蛋白能够与肝癌和正常肝细胞特异性地结合,与其他组织来源的细胞则未见反应。结论CSP是疟原虫子孢子表面主要的蛋白,重组环子孢子蛋白作为原发性肝癌基因治疗的靶向分子具有一定的潜在应用价值。     

外源性五羟色胺大鼠肺出血模型及其与浓度关系

目的　通过外源性五羟色胺 (5 -HT)气管滴入建立新生大鼠肺出血模型及其与浓度关系 .方法　模型制作 :日龄 4～ 5天Wistar二级大鼠 5 0只 ,随机分为 4组 :生理盐水对照组 (A组 )及 3种不同浓度外源性 5 -HT实验组(B、C、D组 ) :经气管导管分别滴入生理盐水和不同浓度 5 -HT ,4小时后处死 ,观察肺大体及组织病理改变 ,将肺出血程度分为 5级 :Ⅰ正常 ;Ⅱ肺水肿 ;Ⅲ点状肺出血 ;Ⅳ局灶性肺出血 ;Ⅴ弥漫性肺出血 ,选择出制作肺出血模型的最佳的浓度 .结果　不同浓度 5 -HT气管内滴入均能引起不同程度肺出血 ,但随着浓度增加 ,B、C、D三组间的肺出血程度无差异 (p >0 .0 5 ) ,其中D组死亡率 30 % ,对照组及B组和C组均无死亡 ,死亡鼠肺为弥漫性出血 .结论　 5 -HT可致大鼠肺出血 ,以 1× 10 -5mol/ml浓度为宜 ,随着 5 -HT浓度增加 ,大鼠死亡率增加 ,但肺出血发生率无差异